Breakthrough Parkinson’s research: Annovis says buntanetap improved cognition in patients with amyloid co-pathology

Annovis Bio, Inc. (NYSE: ANVS) reported new biomarker findings that the company described as evidence of a clinically meaningful link between amyloid co-pathology and faster cognitive decline in Parkinson’s disease patients. The update centered on buntanetap, the company’s lead investigational therapy, and suggested that patients with measurable amyloid burden experienced a steeper trajectory of cognitive impairment prior to treatment but responded more strongly when treated with buntanetap compared with Parkinson’s patients without amyloid involvement. Annovis stated that this population, often representing an under-recognized subtype of the disease, saw cognitive improvements paired with decreases in key neurodegeneration biomarkers including pTau217, total tau and brain-derived tau.

The new biomarker analysis forms part of data from an ongoing Phase 3 clinical trial evaluating buntanetap in early-stage Parkinson’s disease. The company emphasized that roughly one quarter of patients screened showed evidence of amyloid deposition that would typically be associated with Alzheimer’s disease pathology, despite a clinical diagnosis of Parkinson’s. The finding supported Annovis’ view that neurodegenerative diseases may share overlapping biological mechanisms that go beyond current diagnostic labels. The company plans to disclose additional results at a scientific meeting where further information regarding patient subgroup size, cognitive scoring methods and statistical thresholds will be presented.

Why Annovis believes amyloid co-pathology may explain why some Parkinson’s patients experience more rapid cognitive decline according to new trial biomarker evidence

Researchers and clinicians have long observed that cognitive decline is common in Parkinson’s disease, and many patients eventually develop symptoms that resemble Alzheimer’s disease or other dementia syndromes. However, the biological factors behind the different rates of cognitive deterioration have not always been clear. Annovis indicated that the presence of amyloid biomarkers may be a crucial differentiator in the speed and severity of decline. The company noted that patients identified with amyloid co-pathology appeared to experience cognition loss more quickly, suggesting an overlapping mechanism in which amyloid-related toxicity accelerates the neurological damage already associated with Parkinson’s disease.

Annovis described buntanetap as a compound designed to reduce the formation of multiple neurotoxic proteins simultaneously, including amyloid, tau and alpha-synuclein, rather than targeting only one pathological protein. According to the company, this approach may allow buntanetap to intervene earlier across interconnected disease pathways. While the complete biomarker tables are not yet available, Annovis characterized the reductions in pTau217, total tau and brain-derived tau as consistent with a disease-modifying effect. The company communicated that these biomarker shifts aligned with changes in cognitive assessments, suggesting that the biological response was matched by measurable clinical outcomes.

Industry researchers have increasingly discussed the idea that neurodegenerative disorders may operate along a continuum instead of being standalone diseases. Annovis’ analysis may advance that view by showing that a subset of Parkinson’s patients could, in practical terms, be experiencing a mixed pathology that integrates Alzheimer’s-like processes. The implications extend to diagnosis, treatment selection and ultimately, care planning, since patients with overlapping pathology may require specialized interventions that address more than one form of neurotoxicity.

How the new data could influence clinical trial design strategies and increase attention on precision biomarker segmentation in Parkinson’s and Alzheimer’s research

The company stated that the data supports reconsidering how clinical trials for Parkinson’s therapies are structured, particularly those that measure cognitive outcomes. If patients with amyloid co-pathology show more dramatic responses to certain therapeutics, then future studies may benefit from incorporating biomarker-based screening to identify specific treatment-responsive groups. The update has already prompted discussion within the scientific community about whether cognition-focused Parkinson’s trials could adopt enrichment strategies similar to those used in Alzheimer’s disease drug development, where patient selection often depends on biomarker status rather than symptoms alone.

Annovis suggested that the advantages of biomarker segmentation could include more consistent interpretation of cognitive endpoints, more efficient trial enrollment and potentially stronger clinical signals that support regulatory progression. While the company did not claim that this approach would replace broader trial enrollment, it did emphasize that precision stratification could strengthen understanding of where therapies are likely to be most effective. The company is expected to face questions about how such a model might be implemented across different stages of disease, and whether early biomarker detection could guide treatment timing before cognitive decline becomes irreversible.

Investor and market sentiment appeared cautiously constructive following the update, based on commentary within the biotechnology sector. Analysts monitoring the company have noted growing interest in treatments for cognitive symptoms in Parkinson’s disease, given that many available medications primarily target motor symptoms and do not meaningfully alter long-term cognitive progression. While Annovis did not release details regarding commercial strategy or pricing expectations, the company stated that a therapy addressing complex neurodegeneration with a multi-pathway approach may attract strategic interest if later trial phases corroborate the findings.

Why Annovis says buntanetap’s mechanism may support a broader shift toward multi-pathology neurodegenerative treatment models across Parkinson’s and Alzheimer’s care

The new biomarker evidence supports a wider movement in neurology toward therapeutic development that recognizes the biological overlap across multiple neurodegenerative conditions. Annovis has consistently argued that meaningful progress in treating neurological disease may require targeting multiple toxic proteins at once instead of attempting to solve complex disorders through single-mechanism approaches. The company positioned buntanetap as a candidate that aligns with this philosophy, and the new analysis may reinforce that messaging as stakeholders review future data releases.

The company stated that its next steps include preparing updated analyses for presentation to the medical community and continuing trial enrollment and monitoring for durability of cognitive benefit. Several open questions remain, including how long cognitive improvements persist, whether the treatment effect extends to motor symptoms and how patients tolerate buntanetap over longer durations. If additional data confirms sustained benefit and safety, Annovis may engage in deeper regulatory discussions to explore potential accelerated pathways, although the company has not made any formal announcements on that front.

This development contributes to an expanding narrative in neurodegenerative research that diagnostic boundaries may not fully capture disease biology. As research programs advance, there is growing anticipation around whether the next generation of Parkinson’s and Alzheimer’s interventions will be built on cross-pathology models. If so, Annovis’ approach may represent an early example of a treatment aimed at shared neurodegenerative processes instead of isolated disease definitions. Companies across the sector will likely examine whether similar biomarker-defined populations exist in their own trial programs, and if enrichment strategies could improve success rates in historically challenging cognitive endpoints.

Why the upcoming scientific presentation may be a pivotal milestone for Annovis, Parkinson’s clinicians and biomarker-driven neurology research

The company intends to present full biomarker and cognitive data at an upcoming clinical conference, which could provide essential clarity for clinicians, researchers and industry analysts evaluating the broader significance of the findings. Stakeholders will review subgroup definitions, relative effect sizes, cognitive measurement tools and biomarker collection methods, all of which will contribute to assessing whether the results can be replicated at scale. The company also expects to face questions regarding how amyloid co-pathology screening may be incorporated into Parkinson’s clinical practice and whether new diagnostic protocols will be needed before such treatment strategies can be widely adopted.

If future evidence strengthens the association between amyloid burden and accelerated cognitive decline in Parkinson’s disease, the update may influence treatment guidelines and inspire additional clinical investigations into overlapping degenerative mechanisms. While the field remains at an early phase, the interest generated by Annovis’ analysis illustrates how biomarker-driven segmentation may increasingly shape the direction of neurological drug development in the coming years.